Sign in / Join Now
ETFs & Funds
FDA wants more studies on long-term effect. Will $
hold its price anywhere near $1.90?
Ended at $1.35 AH. IMO should rebound in next few days when people understand reality of CRL.
More studies cost more $. Secondary coming.
Add a reply...
Latest StockTalks »
people get DRRX breaking news and analysis by email alert.
Get email alerts on DRRX »
Get latest price
From other sites
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection
at TheStreet (Mon, 3:21PM)
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
at TheStreet (Mon, 7:05AM)
Interesting DRRX Call Options For April 2017
at TheStreet (Aug 22, 2016)
DURECT Corporation: Near-Term Approval Likely for REMOXY
at Investopedia (Jul 5, 2016)
The Wall Street Journal: Pfizer ends agreement to develop Remoxy
at MarketWatch.com (Oct 27, 2014)